00950 LEE'S PHARM
- 1.140
- +0.030+2.70%
LEE'S PHARM News
Lee's Pharmaceutical's 2023 Profit Slumps 67%
Lee's Pharmaceutical Holdings (HKG:0950) recorded a 67% decline in attributable profit for the year ended Dec. 31, 2023, to HK$16.7 million from HK$51.3 million in 2022, a Friday filing on the Hong Ko
李氏大藥廠：2023年年報
LEE'S PHARM To Go Ex-Dividend On May 28th, 2024 With 0.01 HKD Dividend Per Share
March 27th - $LEE'S PHARM(00950.HK)$ is trading ex-dividend on May 28th, 2024. Shareholders of record on May 29th, 2024 will receive 0.01 HKD dividend per share on June 17th, 2024. The ex-dividend
Lee's Pharmaceuticals (00950) will pay a final dividend of HK$0.01 per share on June 17
Lee's Pharmaceutical (00950) announced that it will be distributed on June 17, 2024 until December 2023...
Lee's Pharmaceuticals (00950.HK): Net profit of HK$16.698 million decreased by 67.4% year-on-year in 2023
Gelonghui, March 26, 丨 Lee's Pharmaceutical (00950.HK) announced that for the year ended December 31, 2023, revenue was approximately HK$1,053 million, down 14.6% year on year; profit attributable to company owners was approximately HK$166.98 million, a decrease of 67.4% year on year; basic profit per share was HK2.84 cents, with a proposed final dividend of 1 HK cent per share. During the reporting period, the Group recorded gross profit of HK$551 million, a decrease of 28.5% over the previous year, in line with the decline in sales. The Group's gross margin for the year was 52.4%, down 10.1 from 62.5% in 2022
李氏大藥廠：截至二零二三年十二月三十一日止年度全年業績公佈
Lee's Pharmaceutical Company (00950.HK) plans to hold a board meeting on March 26 to approve the annual results
Glonghui, March 14, 丨 Lee's Pharmaceutical (00950.HK) announced that the company's board of directors meeting will be held on March 26, 2024 (Tuesday) on the 1st floor of Building 20E, Science Park Phase III Science Park East, Shatin, New Territories, Hong Kong to review (including) and approve (if deemed appropriate) the publication of the company's and its subsidiaries' annual results announcements for the year ended 31 December 2023 and consider the proposed final dividend (if any).
LEE'S PHARM: Notice of Board Meeting
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
CITIC Construction Investment: The innovative drug sector has reached the bottom of the valuation to seize multi-line opportunities and focus on systematized pharmaceutical companies entering the harvest period
CITIC Construction Investment released a research report saying that the innovative pharmaceutical industry is expected to achieve good growth in 2024, and is optimistic about the sector's performance.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guotai Junan: The pharmaceutical sector valuation system has entered a small cycle of grasping business operations during a relatively stable period
The Zhitong Finance App learned that Guotai Junan released a research report saying that in 2019-2023, the collection, epidemic, etc. affected industries. It is anticipated that 2024, regardless of whether it has had the greatest positive or negative impact, has passed, returning to the main logic driven by healthcare demand.
CITIC Construction Investment Pharmaceutical's 24-year outlook: moderate growth in the industry, and multiple main lines are expected to take turns
The Zhitong Finance app learned that CITIC Construction Investment released a research report saying that it is optimistic about the pharmaceutical sector in '24 and is optimistic about opportunities for alternating performance in various main lines, such as innovation, overseas travel, improvement, and undervaluation.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Lee's Pharmaceutical Holdings Limited (HKG:950) Surges 29% Yet Its Low P/S Is No Reason For Excitement
Lee's Pharmaceutical Holdings Limited (HKG:950) shares have had a really impressive month, gaining 29% after a shaky period beforehand. Looking further back, the 11% rise over the last twelve month
China Grants Lee's Pharmaceutical Drug Registration for Schizophrenia-Related Agitation Treatment; Shares Rise 3%
China's medical products administrator granted Lee's Pharmaceutical Holdings (HKG:0950) a drug registration certificate for its loxapine powder for the treatment of schizophrenia or bipolar disorder-r
Lee's Pharmaceutical Sells Rights for Eyprotor to Zhaoke Ophthalmology for 60 Million Yuan
Lee's Pharmaceutical Holdings (HKG:0950), through unit, Zhaoke Pharmaceutical (Hefei), agreed to dispose of assets related to ophthalmic drug Eyprotor to an ophthalmic pharmaceutical company for a con
Analysis
Price Target
No Data
